Timing
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
No open-market purchases versus $14.7K in reported salesOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Bjorkquist Jeanette M | PFO and PAO | Jun 17 '26 | Sale | $23.25 | 29 | $674 | 14,560 | Jun 18 04:05 PM |
| Bjorkquist Jeanette M | PFO and PAO | Mar 30 '26 | Sale | $26.69 | 328 | $8,755 | 11,089 | Mar 31 04:25 PM |
| White Nicole S | Chief Manufacturing Officer | Mar 30 '26 |
Company profile
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Sale |
| $26.69 |
| 197 |
| $5,258 |
| 37,477 |
| Mar 31 04:20 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.